We set up experiments to evaluate the effects of defective herpes simplex virus (HSV)-mediated in vitro gene transfer of tissue inhibitor of metalloproteinases-2 (TIMP-2) in malignant glioma cells. Intrinsic TIMPs are known to be inhibitors of the strong invasive activities of matrix metalloproteinases in malignant gliomas. The defective HSV vectors dvSRaTIMP2 was engineered to express human TIMP-2 (hTIMP-2) with a combination of replication-competent HSV mutant, temperature-sensitive HSV-tsK, and amplicon plasmid-containing hTIMP-2. The hTIMP-2 gene was driven by the simian virus 40 promoter. The helper virus (HSV-tsK) was thermosensitive; consequently, this vector could proliferate only at 31.5°C. After infection of U87 human glioblastoma cells with the vector in vitro, expression of TIMP-2 was confirmed by reverse zymography. The U87 cells infected in vitro either with dvSRaTIMP2 or HSV-tsK were efficiently destroyed under replication-permissive conditions (at 31.5°C) and significantly lowered under replication-nonpermissive conditions (at 37°C). The invasive activity of U87 was clearly inhibited by dvSRaTIMP2 infection at both 31.5°C and 37°C. Our studies suggest that TIMP-2 expressing the defective HSV vector is possibly useful for the treatment of malignant brain tumors. Cancer Gene Therapy (2000) 7, 799 -805
G liomas are the most common primary human brain tumors. The prognoses of patients with malignant astrocytoma and glioblastoma multiforme are the poorest of all of the brain tumors, although these tumors rarely metastasize systemically. Because most gliomas, especially glioblastomas, aggressively invade and spread into normal brain parenchyma, from which the margins of the tumor are undistinguishable, it is almost impossible to totally remove these tumors. Because control of these tumors is difficult, local tumors often demonstrate recurrence after initial treatment. This recurrence may contribute to an extremely poor prognosis for patients with malignant glial tumors. Recently, human gene therapy has shown great potential as a therapeutic method for these malignant tumors.
Previous studies have demonstrated that herpes simplex virus-1 (HSV-1) mutants are effective not only for the killing of malignant brain tumors 1, 2 but also for the transfer of a foreign gene to target cells and for ensuring adequate expression of the transferred gene via defective particles. [3] [4] [5] We have tried to develop a more efficient strategy with a replication-competent HSV helper/defective viral system that expresses proteinase inhibitors, resulting in both cytotoxicity and inhibition of invasion.
Invasive tumors are known to produce extracellular matrix-degrading enzymes, such as matrix metalloproteinases (MMPs), 6 -11 heparinases, plasminogen activators, cathepsins, 12 and brain-enriched hyaluronan binding/brevican. 13 The MMP family, especially MMP-2 (72-kDa gelatinase/type IV collagenase/gelatinase A), plays a key role in invasive activity. 6 -8 Tissue inhibitors of metalloproteinases (TIMPs) are secreted by tumor cells and block the activities of MMPs. 8,10,14 -16 In the present study, we demonstrate that human TIMP-2 (hTIMP-2) expression via defective particles inhibits tumor invasion efficiently for the U87 cell line, synchronously with the cytotoxic action of HSV-tsK, which replicates at 31.5°C in vitro.
MATERIALS AND METHODS

Cell lines
Human glioma cell lines (U87, SW1088, and U251) and Vero (African green monkey kidney) cells were obtained from the American Type Culture Collection (Manassas, Va). These cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Nissui Pharmaceuticals, Tokyo, Japan) with 10% heat-inactivated fetal bovine serum and antibiotics (Sigma, St. Louis, Mo) at 37°C. Passages were usually performed twice a week with 0.25% trypsin-ethylenediaminetetraacetic acid solution (Sigma).
pSRaTIMP2 amplicon plasmid construction
A plasmid containing hTIMP-2 cDNA cloned between the EcoRI and the BamHI sites of pSG5 (Stratagene, La Jolla, Calif) was provided by Dr. Seiki (Department of Cancer Cell Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan). pSRaTIMP2 was constructed by inserting a SalI fragment from this plasmid, which has a simian virus 40 promoter upstream and a poly(A) sequence downstream, at the restriction site for SalI of pSRa-ori4 amplicon vector, which was provided by Dr. Samuel D. Rabkin (Department of Neurosurgery, Georgetown University Medical Center, Washington, DC).
Generation of dvSRaTIMP2, hTIMP-2-expressing HSV-1 helper/defective virus vector pSRaTIMP2 amplicon plasmid was transfected into Vero cells using Lipofectamine Plus reagent (Life Technologies, Gaithersburg, Md). After incubation overnight at 37°C, the medium was removed; the cells were superinfected with the HSV-tsK strain (provided by Dr. Subak-Sharpe, Institute of Virology, Glasgow, UK) at a multiplicity of infection (MOI) of 0.2 and cultured at 31.5°C in DMEM with 1% fetal bovine serum. Viral stocks were generated according to the method described by Kaplitt et al. 17 Titration of HSV-tsK helper virus in the viral stocks was determined by a plaque-forming assay at 31.5°C; titration of the defective particles was assayed via immunohistochemical detection of hTIMP-2. hTIMP-2 antibody was obtained from Fuji Chemical Industries (Takaoka, Japan). The primary antibody was visualized by the avidin-biotin complex technique (Vector Laboratories, Burlingame, Calif) with diaminobenzidine tetrahydrochloride. The MOI of helper virus was shown to be that of dvSRaTIMP2. The best stock appeared at passage 5. The titer of the best stock was 3.2 ϫ 10 8 plaque-forming units/mL (helper virus) and 3.3 ϫ 10 6 defective particle units/mL (defective particles), with a defective/helper ratio of 1.0 ϫ 10 Ϫ2 .
Cell culture cytotoxicity
To determine the in vitro cytopathic efficacy of HSV-tsK and dvSRaTIMP2, ϳ1 ϫ 10 4 cells in 1 mL of DMEM with 10% fetal calf serum (FCS) were seeded in a 12-well plate; on the following day, the number of cells was counted in the same manner as on day 0. HSV-tsK or dvSRaTIMP2 was applied to the cells at MOIs of 0.1, 0.5, and 1.0 and cells were cultured at 31.5°C and 37°C. The numbers of viable cells were determined by the trypan blue (Life Technologies, Grand Island, NY) exclusion method on days 1-5. All experiments were performed in triplicate.
Gelatin zymography
Gelatin zymography was performed according to previous reports with modifications. 7, 10, 18 Briefly, the samples were subjected to a 10% sodium dodecyl sulfate polyacrylamide gel containing 0.1% gelatin (Sigma). After electrophoresis at 4°C, gels were washed in 2.5% Triton X-100 at 4°C for 1 hour and incubated in incubation buffer (50 mM tris(hydroxymethyl) aminomethane (pH 7.5), 10 mM CaCl 2 , 1 M ZnCl 2 , 0.02% NaN 3 , and 1 mM phenylmethylsulfonyl fluoride) at 37°C for 20 hours. The gels were then stained with 0.1% Coomassie brilliant blue R-250 (Nacalai Tesque, Kyoto, Japan) and destained in a solution of 10% acetic acid and 50% methanol. The proteolytic activities of the gelatinases were detected as unstained bands.
MMP-2 activities
Cells (1 ϫ 10 5 cells) were placed in 500 L of serum-free DMEM/24-well plates and incubated for 24 hours. Serum-free conditioned medium was centrifuged, and the supernatant was used for gelatin zymography as described above. Each sample was mixed with the same volume of 2ϫ sample buffer without reducing agents, and 10 L of each sample was used for gelatin zymography. Samples were not heated before electrophoresis. The gels were scanned after destaining, and a quantity of MMP-2 was obtained by determination of the lytic zone areas with Adobe PhotoShop (Adobe Systems, San Jose, Calif). The intensity of negative staining is linear in the range of 25-500 U per lane, which was used for quantity for MMP-2 activities.
To determine the difference between the MMP-2 activities at 31.5°C and 37°C, 2 L, 4 L, and 8 L of U87-conditioned media with 2ϫ sample buffer without reducing agents were subjected to electrophoresis at 4°C. Each sample was duplicated on the same gel. After electrophoresis, the gels were treated with Triton X-100 as described above. The gels were then separated, and each gel was immersed in incubation buffer at 31.5°C and 37°C. The intensity of the negative staining bands was measured as described above.
Reverse zymography
The TIMP-2 secreted into the culture medium was detected with reverse zymography. Cells (8 ϫ 10 5 ) in 2 mL of serum-free DMEM were cultured in a 6-well plate with or without viruses at various MOIs for 3 days. Each conditioned medium was centrifuged, and each 20 L of supernatant and 4ϫ sample buffer was used for reverse zymography as follows.
Reverse zymography was performed according to a procedure described previously with modifications. 6, 14 Briefly, the samples and recombinant hTIMP-2 (Fuji Chemical Industries) were subjected to a sodium dodecyl sulfate-15% polyacrylamide gel containing 0.3% gelatin. After electrophoresis at 4°C, gels were incubated in 2.5% Triton X-100 at 4°C for 1 hour and incubated in incubation buffer at 37°C for 20 hours. Next, the gels were destained as described above. With this technique, the dark zones appearing on the gel indicated the presence of gelatinase inhibitors.
Transwell chamber assay
To determine the effects of HSV-tsK-and hTIMP-2-expressing defective virus (dvSRaTIMP2) on U87 cells, we used an in vitro invasion assay system. 6, 10 Six-well transwell chambers (BioCoat; Becton Dickinson Labware, Bedford, Mass) with 8-m pores were coated with Matrigel (100 g/cm 2 ; Becton Dickinson Labware) and allowed to air-dry overnight. The Matrigel was reconstituted with 2 mL of serum-free DMEM at room temperature for 2 hours.
Following the manufacturer's guidelines, 2 mL of cell suspension (8 ϫ 10 5 cells) in serum-free DMEM was added into triplicate upper chamber wells. HSV-tsK or dvSRaTIMP2 was then infected at an MOI of 0.1 at 31.5°C and at an MOI of 1.0 at 37°C.
After 72 hours of incubation at 31.5°C or 37°C, the number of cells attached to the lower well having traversed the filter was counted in 10 random fields at ϫ100 magnification. The percentage of invasion was determined by the ratio of the number of cells infected by each virus invading through the Matrigel insert membrane to the mean number of cells without viral infection migrating through the control insert membrane without Matrigel at the same temperature.
Statistical analysis
Results were expressed as the mean Ϯ SE. Statistical analyses were performed with Student's t test. Statistical significance was set at the 5% level (P Ͻ .05).
RESULTS
In vitro cytopathic efficacy U87 cells showed approximately a 2.5-fold higher growth rate when cultured at 37°C than at 31.5°C. The doubling time was 33.3 hours at 37°C and 84.1 hours at 31.5°C. 7 At 72 hours postinfection, the percentage of surviving U87 cells at 37°C infected with HSV-tsK and dvSRaTIMP2 at an MOI of 1.0 was 84.5 Ϯ 2.9 and 79.8 Ϯ 5.1% (mean Ϯ SE), respectively (Fig 1A) , whereas the percentage of surviving U87 cells at 31.5°C infected with HSV-tsK and dvSRaTIMP2 at an MOI of 0.1 was 72.3 Ϯ 0.2 and 78.1 Ϯ 1.4%, respectively (Fig 1B) .
The method of viral infection has been changed in the study of transwell chamber assay to estimate exact invasion ability. The methodological difference of viral infection between the usual plaque-forming assay and the transwell chamber assay is as follows. Briefly, in the plaque-forming assay, Vero cells were incubated with virus inoculum diluted in 1% FCS/phosphate-buffered saline at 37°C for 60 minutes; after aspiration of virus, cells were incubated with 1% FCS/DMEM at 31.5°C. In the transwell chamber assay, cells were infected by only applying virus to medium. Comparing the efficiency of infection between these methods, the number of cells infected by applying virus to medium was approximately one-third of that infected by plaque-forming assay (data not shown). Viral infection in the cytopathic assay was performed according to the same procedure as the 5) , and 8 L (lanes 3 and 6) of U87-conditioned medium with 2ϫ sample buffer without reducing agents was subjected to electrophoresis. After treatment with Triton X-100, gels were immersed in incubation buffer at 37°C (top) and 31.5°C (bottom) for 20 hours. The intensity of negative staining was linear in each of the three lanes. The ratio of the total MMP-2 activity incubated at 37°C to that at 31.5°C was 1.77 Ϯ 0.05 (mean Ϯ SE).
transwell chamber assay. This fact should be taken into consideration.
MMP-2 activity and expression of hTIMP-2
The MMP-2 activities at 37°C of U87, SW1088, and U251 cells were 3.56 Ϯ 0.22, 2.31 Ϯ 0.20, and 0.98 Ϯ 0.04 U/cell (mean Ϯ SE), respectively. The ratio of the total activity of MMP-2 of U87 cells reacted at 37°C to that at 31.5°C was 1.77 Ϯ 0.05 U/cell (mean Ϯ SE; Fig 2) .
By reverse zymography, the TIMP-2 activity was barely detectable both in the control and in HSV-tsKinfected U87 cells (MOIs of 0.2 and 1.0) at 37°C (Fig 3A,  lanes 2, 3, and 5) . However, by dvSRaTIMP2 infection at an MOI of 1.0, the cells showed a significantly higher expression of hTIMP-2 ( Fig 3A, lane 6) , whereas the expression of TIMP-2 by dvSRaTIMP2 at an MOI of 0.2 was similar to that seen for the samples infected with HSV-tsK (Fig 3A, lane 4) . The difference between hTIMP-2 production in dvSRaTIMP2-infected cells and hTIMP-2 production in HSV-tsK-infected cells at 31.5°C was clearly larger than at 37°C (Fig 3B) . A higher expression of hTIMP-2 was observed by reverse zymography with a higher titer of dvSRaTIMP2 infection.
Transwell chamber assay
The percentage of invasion of cells without any viral infection, with HSV-tsK infection, and with dvSRa-TIMP2 infection through Matrigel membrane at 37°C was 10.2 Ϯ 1.0, 9.1 Ϯ 0.7, and 4.5 Ϯ 0.8% (mean Ϯ SE), respectively (Fig 4A) . Although the invasive activity of HSV-tsK-infected cells was similar to the control (P ϭ .35) at 37°C, the dvSRaTIMP2-infected cells clearly showed a lower invasive activity compared with the others (P Ͻ .0001). At 31.5°C, the percentage of invasion of cells with both viral infections (i.e., 3.4 Ϯ 0.5% with HSV-tsK and 2.6 Ϯ 0.3% with dvSRaTIMP2) was significantly different from the control (6.9 Ϯ 0.7%; Fig  4B; P Ͻ .0001). There was some difference between the groups infected with HSV-tsK and those infected with dvSRaTIMP2, but this difference was not significant (P ϭ .17).
DISCUSSION
In the present study, we demonstrated that the TIMP-2-expressing HSV-1 helper/defective virus vector dvSRa-TIMP2 has both a cytotoxic effect from the replicationcompetent helper virus and an invasive inhibitory effect due to secreted hTIMP-2 in the treatment of a malignant glioma cell line in vitro. The inhibition was clearly demonstrated by an invasion assay with the Matrigel basement membrane method.
Replication-defective HSV vectors have been widely used as gene-transfer vehicles into the central nervous system. The expression of immediate early genes from the helper virus may produce some toxicity in certain cell types, particularly at higher MOIs. 19 We remarked that the toxicity is useful to kill malignant tumor cells specifically, and we subsequently combined the replicationcompetent HSV-1 mutant with TIMP-2-expressing defective particles as an HSV-1 helper/defective virus vector.
Previous studies demonstrated that glioma cells express MMPs (especially MMP-2) that degrade the extracellular matrix and promote invasion. 6 -9,16 The malignancy of the glioma was proportional to the gelatinase A mRNA expression. 15 The total activities of MMP-2 in the culture media of human glioma cell lines were quantified easily by gelatin zymography.
The activity of the MMP-2 secreted from U87 cells at 37°C was approximately twice that seen at 31.5°C (Fig 2) , probably resulting in active invasion without viral infection at 37°C. Temperature-sensitive HSV-tsK is able to replicate and produce cell lysis at 31.5°C but not at 37°C. 20, 21 This is why the percentage of invasion of U87 cells infected with HSV-tsK remarkably decreased at 31.5°C (invasion index ϭ 50.0%) compared with that at 37°C (invasion index ϭ 89.1%), even with an MOI that was 10 times higher. From the cell survival curve, HSV-tsK demonstrated very low cytotoxicity at 37°C (Fig 1) .
According to Matrigel assay at 37°C, dvSRaTIMP2 infection remarkably inhibited the invasive activity of U87, whereas HSV-tsK did not show any significant inhibition. It was suggested that a large enough amount of hTIMP-2 was produced by defective viral particles at the high MOI to inhibit invasion, whereas only slightly higher activity was observed at 37°C by reverse zymography (Fig 3A) . Although hTIMP-2 secretion at 31.5°C increased clearly from the dvSRaTIMP2-infected U87 cells, the percentage of invasion by dvSRaTIMP2-infected cells was not significantly decreased. At 31.5°C, the number of surviving cells decreased to 60 -70% due to the cytotoxic effect of the helper particles (Fig 1B) . Therefore, we probably could not detect significant inhibition of invasion despite the high TIMP-2 expression under this condition. Nakagawa et al 10 have shown that the invasive activity of another human glioma cell line (T98G) was inhibited with recombinant TIMP-2 (rTIMP-2), but not rTIMP-1 in a dose-dependent manner.
By infection with dvSRaTIMP2, the percentage of invasion decreased clearly in the Matrigel transwell chamber assay. As shown in Figure 1 , the number of surviving cells after infection with dvSRaTIMP2 was similar to that seen after infection with HSV-tsK. This result supported a previous report indicating that addition of rTIMP-2 to the medium had no effect on glioma cell growth. 10 Collectively, the inhibition of invasion by dvSRaTIMP2 infection resulted from the inhibitory activity of hTIMP-2 to MMP-2, but not cell growth inhibition.
We demonstrated that dvSRaTIMP2 under replication-permissive conditions had a more potent ability to .35 ), but the difference between HSV-tsK and dvSRaTIMP2 was significant (P Ͻ .0001). B: A significant difference was detected between the control group and the other groups because of the cytotoxicity of HSV-tsK at 31.5°C. dvSRaTIMP2 had a tendency to decrease the number of cells traversing through Matrigel compared with HSV-tsK-infected cells, but the difference was not significant (P ϭ .17). The numbers contained in the black bars are invasion indices when the percentage of invasion of control was set at 100% (mean Ϯ SE).
inhibit U87 invasion than under replication-nonpermissive conditions. However, several tasks still remain to be completed.
First, temperature-sensitive HSV-tsK is barely able to replicate at normal human body temperature, but it can replicate at 31.5°C. Considering the experiments in vivo, it is therefore necessary to use an HSV that can replicate at 37°C.
Second, because the ratio of defective particle to helper virus in the viral stocks used in this study was low, a significant difference in the percentage of invasion was not seen between the tsK-infected group and the dvSRaTIMP2-infected group at 31.5°C. It is important to generate stocks with a higher ratio of defective particles because HSV infection at higher MOIs may reveal more cytotoxicity to normal cells as a result of its IE genes. 19 Third, to reduce the activity of cell lysis by certain HSV-1 mutants themselves, it is useful to use HSV mutants that can replicate only in tumor cells and not in normal cells. An attenuated, multimutated HSV-G207 1 that is replication-competent in glioblastoma cells and other dividing cells provides additional safety features such as attenuated neurovirulence, temperature sensitivity and ganciclovir hypersensitivity, and the presence of an easily detectable histochemical marker, the lacZ gene. HSV-G207 was also effective for the treatment of intracranial malignant meningiomas without inflammation, hemorrhage, or other pathological effects in the surrounding normal brain tissue.
2 HSV-G207 might be used as a helper virus in this study.
Fourth, most people of Ͼ40 years of age are presumed to be infected with HSV-1. In the presence of wild-type HSV-1 and HSV-1 antibody, we should consider two possibilities regarding gene therapy via HSV. First, the revertants arise frequently (10 Ϫ5 -10
Ϫ6
) and are related to the extent of overlapping homology between the integrated gene and the wild-type gene. [22] [23] [24] The application of multimutated HSV, rather than singlemutated HSV, can decrease it remarkably. Second, under the existence of HSV antibodies, a recombinant HSV-1 vector might not be able to deliver transgenes into glioma cells. Herrlinger et al 25 reported that under preimmunization conditions, the HSV-1 vector was greatly, but not completely, reduced. Our newly developed HSV-1 helper/defective virus vector system should basically have high potential to strengthen replicationcompetent viral therapy strategy with HSV-1.
Replication-competent HSV-1 demonstrated cytotoxic effects and hTIMP-2-expressing defective particles showed the ability to inhibit the invasive activities of MMPs. Our results demonstrated that hTIMP-2 expressed by defective particles with a replication-competent helper virus had advantages of both cytotoxicity and invasion inhibition. The hTIMP-2-expressing replication-competent HSV-1 helper/defective system is expected to be clinically useful for the treatment of malignant brain tumors when generated with attenuated, multimutated HSV (e.g., HSV-G207), which replicates only in highly proliferating tumor cells in vivo.
